Effects of hormone therapy containing 2 mg drospirenone and 1 mg 17β‑estradiol on postmenopausal exacerbation of Meniere's disease: Preliminary study

Grillo,Caterina Maria; Maiolino,Luigi; Rapisarda,Agnese Maria Chiara; Caruso,Giuseppe; Palermo,Gaia; Caruso,Salvatore

doi:10.3892/etm.2021.10537

Effects of hormone therapy containing 2 mg drospirenone and 1 mg 17β‑estradiol on postmenopausal exacerbation of Meniere's disease: Preliminary study

Authors:
- Caterina Maria Grillo
- Luigi Maiolino
- Agnese Maria Chiara Rapisarda
- Giuseppe Caruso
- Gaia Palermo
- Salvatore Caruso
View Affiliations

Affiliations: Department of Medical and Surgical Sciences and Advanced Technologies ‘G. Ingrassia’, ENT Section, University of Catania, I-95124 Catania, Italy, Department of General Surgery and Medical Surgical Specialties, Gynecological Clinic, Research Group for Sexology, University of Catania, I-95124 Catania, Italy, Department BIOMETEC, University of Catania, I-95124 Catania, Italy
Published online on: August 2, 2021 https://doi.org/10.3892/etm.2021.10537
Article Number: 1103
Copyright: © Grillo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the effects of 2 mg drospirenone (DRSP) and 1 mg 17β‑estradiol (E2) hormone therapy (HT) in combination with rehabilitation therapy for postmenopausal women with Meniere's disease (MD). The combined drug hormone treatment was denoted as DRSP/E2. A total of 65 postmenopausal female patients with MD and severe distress were enrolled in the present prospective study. A total of 31 women comprised the study group (group A), undergoing HT and rehabilitation therapy, whereas 34 women who opted for rehabilitation therapy alone comprised the control group (group B). Vestibular function and distress associated with MD were assessed by stabilometry and the Dizziness Handicap Inventory (DHI) questionnaire, respectively. The data were collected at baseline and during the 3‑ and 6‑month follow‑up visits. The areas of the stabilometric ellipses exhibited a higher reduction in group A compared with group B with regard to the baseline values at both follow‑up assessments (P<0.001). At baseline, both groups exhibited severe self‑perceived discomfort, with similar DHI scores of 72.3±3.7 (group A) and 70.6±3.9 (group B; P=0.07). At the 3‑month follow‑up, both groups underwent a gradual improvement, which was significantly higher in group A (47.5±3.7) compared with in group B (64.2±3.3; P<0.001). At the 6‑month follow‑up, the DHI scores were improved in group A (43.4±3.4) compared with in group B (58.5±3.1; P<0.001). Therefore, DRSP/E2 HT was effective in reducing the fluid overload, which is characteristic of MD. The findings of the present study demonstrated that integrated therapy based on the administration of DRSP/E2 HT and rehabilitation may be more effective compared with rehabilitation alone for the management of postmenopausal exacerbation of MD.

View Figures

View References

1	Hale GE, Zhao X, Hughes CL, Burger HG, Robertson DM and Fraser IS: Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the staging of reproductive Aging workshop (STRAW) staging system. J Clin Endocrinol Metab. 92:3060–3067. 2007.PubMed/NCBI View Article : Google Scholar
2	National Institutes of Health. National Institute of Health State-of-the-Science Conference statement: Management of menopause-related symptoms. Ann Intern Med. 142:1003–1013. 2005.PubMed/NCBI
3	Ekblad S, Bergendabl A, Enler P, Ledin T, Möllen C and Hammar M: Disturbances in postural balance are common in postmenopausal women with vasomotor symptoms. Climacteric. 3:192–198. 2000.PubMed/NCBI View Article : Google Scholar
4	Muncie HL, Sirmans SM and James E: Dizziness: Approach to evaluation and management. Am Fam Physician. 95:154–162. 2017.PubMed/NCBI
5	Bruderer SG, Bodmer D, Stohler NA, Jick SS and Meier CR: Population-based study on the epidemiology of Ménière's disease. Audiol Neurootol. 22:74–82. 2017.PubMed/NCBI View Article : Google Scholar
6	Lopez-Escamez JA, Carey J, Chung WH, Goebel JA, Magnusson M, Mandalà M, Newman-Toker DE, Strupp M, Suzuki M, Trabalzini F, et al: Diagnostic criteria for Menière's disease. J Vestib Res. 25:1–7. 2015.PubMed/NCBI View Article : Google Scholar
7	Jian H, Yu G, Chen G, Lin N and Wang H: Correlation between auditory-vestibular functions and estrogen levels in postmenopausal patients with Meniere's disease. J Clin Lab Anal. 33(e22626)2019.PubMed/NCBI View Article : Google Scholar
8	Shojaku H, Watanabe Y, Fujisaka M, Tsubota M, Kobayashi K, Yasumura S and Mizukoshi K: Epidemiologic characteristics of definite Meniere's disease in Japan. A long-term survey of Toyama and Niigata prefectures. ORL J Otorhinolaryngol Relat Spec. 67:305–309. 2005.PubMed/NCBI View Article : Google Scholar
9	Baber RJ, Panay N and Fenton A: IMS Writing Group. 2016 IMS recommendations on women's midlife health and menopause hormone therapy. Climacteric. 19:109–150. 2019.PubMed/NCBI View Article : Google Scholar
10	Foidart JM: Added benefits of drospirenone for compliance. Climacteric 8 Suppl. 3:S28–S34. 2005.PubMed/NCBI View Article : Google Scholar
11	Sitruk-Ware R: Pharmacology of different progestogens: The special case of drospirenone. Climacteric. 8 (Suppl 3):S4–S12. 2005.PubMed/NCBI View Article : Google Scholar
12	Palacios S, Foidart JM and Genazzani AR: Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas. 55:297–307. 2006.PubMed/NCBI View Article : Google Scholar
13	Archer DF: Drospirenone and estradiol: A new option for the postmenopausal woman. Climacteric. 10 (Suppl 1):S3–S10. 2007.PubMed/NCBI View Article : Google Scholar
14	Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P and Behre HM: The menopause rating scale (MRS): Comparison with Kupperman index and quality-of-life scale SF-36. Climacteric. 3:50–58. 2000.PubMed/NCBI View Article : Google Scholar
15	Semont A, Freyss G and Vitte E: Curing the BPPV with a liberatory maneuver. Adv Otorhinolaryngol. 42:290–293. 1988.PubMed/NCBI View Article : Google Scholar
16	Zhang X, Qian X, Lu L, Chen J, Liu J, Lin C and Gao X: Effects of Semont maneuver on benign paroxysmal positional vertigo: A meta-analysis. Acta Otolaryngol. 137:63–70. 2017.PubMed/NCBI View Article : Google Scholar
17	Kapteyn TS, Bles W, Njiokiktjien CJ, Kodde L, Massen CH and Mol JM: Standardization in platform stabilometry being a part of posturography. Agressologie. 24:321–326. 1983.PubMed/NCBI
18	Prieto TE, Myklebust JB, Hoffmann RG, Lovett EG and Myklebust BM: Measures of postural steadiness: Differences between healthy young and elderly adults. IEEE Trans Biomed Eng. 43:956–966. 1996.PubMed/NCBI View Article : Google Scholar
19	Jacobson GP and Newman CW: The development of the Dizziness handicap inventory. Arch Otolaryngol Head Neck Surg. 116:424–427. 1990.PubMed/NCBI View Article : Google Scholar
20	Foster CA: Optimal management of Ménière's disease. Ther Clin Risk Manag. 11:301–307. 2015.PubMed/NCBI View Article : Google Scholar
21	Miyashita T, Inamoto R, Fukuda S, Hoshikawa H, Hitomi H, Kiyomoto H, Nishiyama A and Mori N: Hormonal changes following a low-salt diet in patients with Ménière's disease. Auris Nasus Larynx. 44:52–57. 2017.PubMed/NCBI View Article : Google Scholar
22	Pullen RL Jr: Navigating the challenges of Meniere disease. Nursing. 47:38–45. 2017.PubMed/NCBI View Article : Google Scholar
23	Watanabe I: Ménière's disease in males and females. Acta Otolaryngol. 91:511–514. 1981.PubMed/NCBI View Article : Google Scholar
24	Basura GJ, Adams ME, Monfared A, Schwartz SR, Antonelli PJ, Burkard R, Bush ML, Bykowski J, Colandrea M, Derebery J, et al: Clinical practice guideline: Ménière's disease. Otolaryngol Head Neck Surg. 162 (Suppl 2):S1–S55. 2020.PubMed/NCBI View Article : Google Scholar
25	Caruso S, Mauro D, Maiolino L, Grillo C, Rapisarda AMC and Cianci S: Effects of combined oral contraception containing drospirenone on premenstrual exacerbation of Meniere's disease: Preliminary study. Eur J Obstet Gynecol Reprod Biol. 224:102–107. 2018.PubMed/NCBI View Article : Google Scholar
26	Farage MA, Neill S and MacLean AB: Physiological changes associated with the menstrual cycle: A review. Obstet Gynecol Surv. 64:58–72. 2009.PubMed/NCBI View Article : Google Scholar
27	Smith MJ, Keel JC, Greenberg BD, Adams LF, Schmidt PJ, Rubinow DA and Wassermann EM: Menstrual cycle effects on cortical excitability. Neurology. 53:2069–2072. 1999.PubMed/NCBI View Article : Google Scholar
28	Al-Mana D, Ceranic B, Djahanbakhch O and Luxon LM: Hormones and the auditory system: A review of physiology and pathophysiology. Neuroscience. 153:881–900. 2008.PubMed/NCBI View Article : Google Scholar
29	Caruso S, Cianci A, Grasso D, Agnello C, Galvani F, Maiolino L and Serra A: Auditory brainstem response in postmenopausal women treated with hormone replacement therapy: A pilot study. Menopause. 7:178–183. 2000.PubMed/NCBI View Article : Google Scholar
30	Caruso S, Maiolino L, Agnello C, Garozzo A, Di Mari L and Serra A: Effects of patch or gel estrogen therapies on auditory brainstem response in surgically postmenopausal women: A prospective, randomized study. Fertil Steril. 79:556–561. 2003.PubMed/NCBI View Article : Google Scholar
31	Aoki M, Asai M, Nishihori T, Mizuta K, Ito Y and Ando K: The relevance of an elevation in the plasma vasopressin levels to the pathogenesis of Meniere's attack. J Neuroendocrinol. 19:901–906. 2007.PubMed/NCBI View Article : Google Scholar
32	Canlon B and Frisina RD: Sex hormones and hearing: A pioneering area of enquiry. Hear Res. 252:1–4. 2009.PubMed/NCBI View Article : Google Scholar
33	Caruso S, Serra A, Grillo C, De Leo V, Maiolino L, Agnello C and Cianci A: Prospective study evaluating olfactometric and rhinomanometric outcomes in postmenopausal women on 1 mg 17beta-estradiol and 2 mg drospirenone HT. Menopause. 15:967–972. 2008.PubMed/NCBI View Article : Google Scholar
34	Nelson HD, Humphrey LL, Nygren P, Teutsch SM and Allan JD: Postmenopausal hormone replacement therapy. Scientific review. JAMA. 288:872–881. 2002.PubMed/NCBI View Article : Google Scholar
35	Kim SY, Han SH, Kim YH and Park MH: Clinical features of recurrence and osteoporotic changes in benign paroxysmal positional vertigo. Auris Nasus Larynx. 44:156–161. 2016.PubMed/NCBI View Article : Google Scholar
36	Yu S, Liu F, Cheng Z and Wang Q: Association between osteoporosis and benign paroxysmal positional vertigo: A systematic review. BMC Neurol. 14(110)2014.PubMed/NCBI View Article : Google Scholar
37	Vignozzi L, Malavolta N, Villa P, Mangili G, Migliaccio S and Lello S: Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO. J Endocrinol Invest. 42:609–618. 2019.PubMed/NCBI View Article : Google Scholar
38	Liu DH, Kuo CH, Wang CT, Chiu CC, Chen TJ, Hwang DK and Kao CL: Age-related increases in benign paroxysmal positional vertigo are reversed in women taking estrogen replacement therapy: A population-based study in Taiwan. Front Aging Neurosci. 9(404)2017.PubMed/NCBI View Article : Google Scholar